<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estimated comparative daily doses for inhaled glucocorticoids in adolescents ≥12 years and adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estimated comparative daily doses for inhaled glucocorticoids in adolescents ≥12 years and adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Estimated comparative daily doses for inhaled glucocorticoids in adolescents ≥12 years and adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="40%"></colgroup><colgroup span="3" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Low dose<br/> (total daily dose)</td> <td class="subtitle1">Medium dose<br/> (total daily dose)</td> <td class="subtitle1">High dose<br/> (total daily <span style="white-space: nowrap;">dose)*</span></td> </tr> <tr class="divider_top"> <td> <p><strong>Beclomethasone HFA</strong><br/> (Qvar RediHaler product available in United States)</p> <p>Administer as 2 divided doses</p> </td> <td>80 to 160 mcg</td> <td>&gt;160 to 320 mcg</td> <td>&gt;320 to 640 mcg</td> </tr> <tr> <td class="indent1">40 mcg per actuation</td> <td>2 or 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">80 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>6 or 8 inhalations</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td> <p><strong>Beclomethasone HFA</strong><sup>Δ</sup><br/> (Qvar product available in Canada, Europe, and elsewhere)</p> <p>Administer as 2 divided doses</p> </td> <td>100 to 200 mcg</td> <td>&gt;200 to 400 mcg</td> <td>&gt;400 to 800 mcg</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">50 mcg per actuation</td> <td>2 to 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="divider_bottom highlight_lght_gray_text highlight_gray_text"> <td class="indent1">100 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>6 or 8 inhalations</td> </tr> <tr> <td> <p><strong>Budesonide DPI</strong><br/> (Pulmicort Flexhaler product available in United States)</p> <p>Administer as 2 divided doses</p> </td> <td>180 to 360 mcg</td> <td>&gt;360 to 720 mcg</td> <td>&gt;720 to 1440 mcg</td> </tr> <tr> <td class="indent1">90 mcg per actuation</td> <td>2 or 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">180 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>6 or 8 inhalations</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td> <p><strong>Budesonide DPI</strong><sup>Δ</sup><br/> (Pulmicort Turbuhaler or Turbohaler product available in Canada, Europe, and elsewhere)</p> <p>Administer low doses (ie, ≤400 mcg/day) once daily; administer higher doses (ie, &gt;400 mcg/day) as 2 to 4 divided doses</p> </td> <td>200 to 400 mcg</td> <td>&gt;400 to 800 mcg</td> <td>&gt;800 to 2400 mcg</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">100 mcg per actuation</td> <td>2 to 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">200 mcg per actuation</td> <td>1 to 2 inhalations</td> <td>3 to 4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom highlight_lght_gray_text highlight_gray_text"> <td class="indent1">400 mcg per actuation</td> <td>1 inhalation </td> <td>2 inhalations</td> <td>3 to 6 inhalations</td> </tr> <tr> <td> <p><strong>Ciclesonide HFA</strong><br/> (Alvesco product available in United States, Europe, and elsewhere)</p> <p>United States: Administer as 2 divided doses</p> <p>Australia, Europe, and elsewhere: Administer lower doses (ie, 160 to 320 mcg/day) once daily; administer 640 mcg dose as 2 divided doses</p> </td> <td>160 mcg</td> <td>320 mcg</td> <td>640 mcg</td> </tr> <tr> <td class="indent1">80 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">160 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>4 inhalations</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td> <p><strong>Ciclesonide HFA</strong><sup>Δ</sup><br/> (Alvesco product available in Canada)</p> <p>Administer lower doses (eg, 100 to 400 mcg) once daily; administer 800 mcg dose as 2 divided doses</p> </td> <td>100 to 200 mcg</td> <td>&gt;200 to 400 mcg</td> <td>&gt;400 to 800 mcg</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">100 mcg per actuation</td> <td>1 to 2 inhalations</td> <td>3 to 4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom highlight_lght_gray_text highlight_gray_text"> <td class="indent1">200 mcg per actuation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>3 to 4 inhalations</td> </tr> <tr> <td> <p><strong>Fluticasone propionate HFA</strong><br/> (Flovent HFA product available in United States)</p> <p>Administer as 2 divided doses</p> </td> <td>176 to 220 mcg</td> <td>&gt;220 to 440 mcg</td> <td>&gt;440 to 1760 mcg</td> </tr> <tr> <td class="indent1">44 mcg per actuation</td> <td>4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr> <td class="indent1">110 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">220 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>4 to 8 inhalations</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td> <p><strong>Fluticasone propionate HFA</strong><sup>Δ</sup><br/> (Flovent HFA product available in Canada; Flixotide Evohaler product available in Europe and elsewhere)</p> <p>Administer as 2 divided doses</p> </td> <td>100 to 250 mcg</td> <td>&gt;250 to 500 mcg</td> <td>&gt;500 to 2000 mcg</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">50 mcg per actuation</td> <td>2 to 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">125 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom highlight_lght_gray_text highlight_gray_text"> <td class="indent1">250 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>4 to 8 inhalations</td> </tr> <tr> <td> <p><strong>Fluticasone propionate DPI</strong><br/> (Flovent Diskus product available in United States and Canada; Flixotide Accuhaler product available in Europe and elsewhere)</p> <p>Administer as 2 divided doses</p> </td> <td>100 to 250 mcg</td> <td>&gt;250 to 500 mcg</td> <td>&gt;500 to 2000 mcg</td> </tr> <tr> <td class="indent1">50 mcg per actuation</td> <td>2 to 4 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr> <td class="indent1">100 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>¶</td> </tr> <tr> <td class="indent1">250 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>4 to 8 inhalations</td> </tr> <tr class="divider_bottom"> <td class="indent1">500 mcg per actuation (strength not available in United States)</td> <td>◊</td> <td>◊</td> <td>2 or 4 inhalations</td> </tr> <tr> <td> <p><strong>Fluticasone propionate DPI</strong><br/> (Armonair Digihaler product available in United States; Aermony Respiclick product available in Canada)</p> <p>Administer as 2 divided doses</p> </td> <td>110 mcg</td> <td>226 mcg</td> <td>464 mcg</td> </tr> <tr> <td class="indent1">55 mcg per actuation</td> <td>2 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr> <td class="indent1">113 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">232 mcg per actuation</td> <td>◊</td> <td>◊</td> <td>2 inhalations</td> </tr> <tr> <td> <p><strong>Fluticasone furoate DPI</strong><br/> (Arnuity Ellipta product available in United States, Canada, Australia, and elsewhere, but not available in Europe or UK)</p> <p>Administer once daily</p> <p><strong>NOTE:</strong> Inhaled fluticasone furoate has a greater anti-inflammatory potency per microgram than fluticasone propionate inhalers. Thus, fluticasone furoate is administered at a lower daily dose and used only once daily.</p> </td> <td>50 mcg (by use of pediatric DPI, which is off-label in adolescents and adults)</td> <td>100 mcg</td> <td>200 mcg</td> </tr> <tr> <td class="indent1">50 mcg per actuation</td> <td>1 inhalation</td> <td>¶</td> <td>¶</td> </tr> <tr> <td class="indent1">100 mcg per actuation</td> <td>◊</td> <td>1 inhalation</td> <td>2 inhalations</td> </tr> <tr class="divider_bottom"> <td class="indent1">200 mcg per actuation</td> <td>◊</td> <td>◊</td> <td>1 inhalation</td> </tr> <tr> <td> <p><strong>Mometasone DPI</strong><br/> (Asmanex Twisthaler product available in United States)</p> <p>May administer lower doses (ie, 220 to 440 mcg/day) once daily; administer 880 mcg dose as 2 divided doses</p> </td> <td>220 mcg</td> <td>&gt;220 to 440 mcg</td> <td>&gt;440 to 880 mcg</td> </tr> <tr> <td class="indent1">110 mcg per actuation</td> <td>2 inhalations</td> <td>¶</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">220 mcg per actuation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>4 inhalations</td> </tr> <tr> <td> <p><strong>Mometasone HFA</strong><br/> (Asmanex HFA product available in United States)</p> <p>Administer as 2 divided doses</p> </td> <td>200 mcg</td> <td>&gt;200 to 400 mcg</td> <td>&gt;400 to 800 mcg</td> </tr> <tr> <td class="indent1">100 mcg per actuation</td> <td>2 inhalations</td> <td>4 inhalations</td> <td>¶</td> </tr> <tr class="divider_bottom"> <td class="indent1">200 mcg per actuation</td> <td>◊</td> <td>2 inhalations</td> <td>4 inhalations</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td> <p><strong>Mometasone DPI</strong><sup>Δ</sup><br/> (Asmanex Twisthaler product available in Canada, Europe, and elsewhere)</p> <p>May administer lower doses (ie, 200 to 400 mcg/day) once daily; administer 800 mcg dose as 2 divided doses</p> </td> <td>200 mcg</td> <td>&gt;200 to 400 mcg</td> <td>&gt;400 to 800 mcg</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">200 mcg per actuation</td> <td>1 inhalation</td> <td>2 inhalations</td> <td>¶</td> </tr> <tr class="highlight_lght_gray_text highlight_gray_text"> <td class="indent1">400 mcg per actuation</td> <td>◊</td> <td>1 inhalation</td> <td>2 inhalations</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li><strong>The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy.</strong> The clinician must monitor the patient's response on several clinical parameters and adjust the dose accordingly. The stepwise approach to therapy emphasizes that once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.</li>
<li>Suggested total daily doses for low, medium, and high dose inhaled glucocorticoid regimens are based on daily doses recommended by Global Initiative for Asthma (GINA), National Asthma Education and Prevention Program (NAEPP), and/or product labeling<sup>[1-5]</sup>. This is not a table of equivalence.</li>
<li>Depending on the specific product, total daily doses are administered once or divided and given twice daily. Refer to local product information or a clinical drug reference (eg, Lexicomp).</li>
<li>Some doses are outside the approved product information recommendations.</li>
</ul></div><div class="graphic_footnotes"><p>DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant metered dose inhaler.</p>
<p>* Evidence for additional improvement with dose increases &gt;1000 mcg/day is limited.</p>
<p>¶ Select alternate preparation with higher mcg/actuation to improve convenience.</p>
<p>Δ Products shaded in light gray color are not available in the United States but are available widely elsewhere.</p>
	
	◊ Select preparation with fewer mcg/actuation.</div><div class="graphic_reference">Data from:
<ol>
<li>Global Initiative for Asthma (GINA); Global Strategy for Asthma Management and Prevention; 2021. Available at <a href="http://www.ginasthma.org" target="_blank">www.ginasthma.org</a>.</li>
<li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma; 2007. NIH Publication 08-4051 available at http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report and pro.</li>
<li>US Food &amp; Drug Administration (FDA) approved product information. US National Library of Medicine. (Available online at <a href="http://www.dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">www.dailymed.nlm.nih.gov/dailymed/index.cfm</a>.)</li>
<li>Health Canada-approved product monograph. Health Canada. (Available online at <a href="https://health-products.canada.ca/dpd-bdpp/index-eng.jsp" target="_blank">https://health-products.canada.ca/dpd-bdpp/index-eng.jsp</a>.)</li>
<li>European Medicines Agency (EMA) summary of product characteristics. European Medicines Agency. (Available online at <a href="http://www.ema.europa.eu/en/medicines" target="_blank">www.ema.europa.eu/en/medicines</a>.)</li>
</ol></div><div id="graphicVersion">Graphic 78011 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
